[go: up one dir, main page]

FI20165814A7 - Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa - Google Patents

Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa Download PDF

Info

Publication number
FI20165814A7
FI20165814A7 FI20165814A FI20165814A FI20165814A7 FI 20165814 A7 FI20165814 A7 FI 20165814A7 FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A7 FI20165814 A7 FI 20165814A7
Authority
FI
Finland
Prior art keywords
interleukin
prognostic
oncolytic
vectors
compositions
Prior art date
Application number
FI20165814A
Other languages
English (en)
Swedish (sv)
Other versions
FI20165814A (fi
Inventor
Kristian Taipale
Akseli Hemminki
Original Assignee
Tilt Biotherapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilt Biotherapeutics Oy filed Critical Tilt Biotherapeutics Oy
Priority to FI20165814A priority Critical patent/FI20165814A/fi
Priority to PCT/FI2017/050742 priority patent/WO2018078220A1/en
Publication of FI20165814A7 publication Critical patent/FI20165814A7/fi
Publication of FI20165814A publication Critical patent/FI20165814A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esillä oleva keksintö liittyy onkolyyttiseen virusvektoriin, joka käsittää interleukiinia 8 neutralisoivaa vasta-ainetta koodaavan nukleiinihapposekvenssin. Lisäksi, esillä oleva keksintö liittyy interleukiini 8:n käyttöön prognostiivisena ja ennustavana biomarkkerina onkolyyttisessä immunoterapiassa. Tässä suhteessa, esillä oleva keksintö koskee menetelmää, jossa analysoidaan onko syövästä kärsivä kohde responsiivinen vai eiresponsiivinen hoidolle onkolyyttisellä virusvektorilla, ja menetelmää onkolyyttisen immunoterapian tehokkuuden seuraamiseksi.
FI20165814A 2016-10-27 2016-10-27 Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa FI20165814A (fi)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20165814A FI20165814A (fi) 2016-10-27 2016-10-27 Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa
PCT/FI2017/050742 WO2018078220A1 (en) 2016-10-27 2017-10-27 Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20165814A FI20165814A (fi) 2016-10-27 2016-10-27 Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa

Publications (2)

Publication Number Publication Date
FI20165814A7 true FI20165814A7 (fi) 2018-04-28
FI20165814A FI20165814A (fi) 2018-04-28

Family

ID=60569934

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20165814A FI20165814A (fi) 2016-10-27 2016-10-27 Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa

Country Status (2)

Country Link
FI (1) FI20165814A (fi)
WO (1) WO2018078220A1 (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
CN108064275A (zh) 2014-09-24 2018-05-22 萨克生物研究学院 溶瘤肿瘤病毒及使用方法
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
AU2019378732A1 (en) * 2018-11-12 2021-05-27 Aptarion Biotech Ag CXCL8 binding nucleic acids
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
SG11202110697UA (en) * 2019-03-28 2021-10-28 Mayo Found Medical Education & Res Ifnbeta as a pharmacodynamic marker in vsv-ifnbeta-nis oncolytic therapy
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
CN114518451B (zh) * 2021-12-22 2025-09-26 厦门福宸百奥生物技术有限公司 检测人5型腺病毒中和抗体的试纸条、检测卡、试剂盒及其制备方法
WO2025012635A1 (en) * 2023-07-11 2025-01-16 Theolytics Ltd Adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096781A1 (en) * 2001-08-31 2003-05-22 University Of Southern California IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
JP4739763B2 (ja) 2002-12-16 2011-08-03 ゲンマブ エー／エス インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
US9345787B2 (en) * 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
CN103221423B (zh) * 2010-09-24 2015-09-30 昂克斯治疗有限公司 溶瘤腺病毒载体及与其相关的方法和用途
US20150266961A1 (en) * 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
KR101458947B1 (ko) 2013-03-05 2014-11-12 국립암센터 인터루킨-８ 앱타머 및 이의 용도
RU2703438C2 (ru) 2013-04-18 2019-10-16 Тилт Байотерапьютикс Ой Расширенная адоптивная клеточная терапия
JP6754532B2 (ja) 2015-03-17 2020-09-16 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用

Also Published As

Publication number Publication date
WO2018078220A1 (en) 2018-05-03
FI20165814A (fi) 2018-04-28

Similar Documents

Publication Publication Date Title
FI20165814A7 (fi) Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa
MX2025005375A (es) Variantes de desoxirribonucleasa (dnasa)
EP3950941A3 (en) Dnase polypeptide variants
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
MX2018008051A (es) Variantes de beta-glucanasa y polinucleotidos que las codifican.
MX2023007728A (es) Composiciones para el tratamiento de esclerosis lateral amiotrofica (ela).
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
SG10201909180SA (en) Humanized anti-c1s antibodies and methods of use thereof
MX2019000140A (es) Variantes de xilanasa y polinucleotidos que las codifican.
IL271031A (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
PH12019500269A1 (en) Production method for insoluble recombinant protein aggregate
PH12018501070A1 (en) Anti-pcsk9 antibody and use thereof
MX2020003508A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
WO2018017747A3 (en) Oncolytic viruses targeting stat3
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
NZ746609A (en) Ilt7 binding molecules and methods of using the same
HK1231555A1 (zh) 生物标志物及其用途
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
PH12017500309A1 (en) Anti-vasa antibodies, and methods of production and use thereof
PH12018500155A1 (en) Recombinant orf virus vector
EA201990730A1 (ru) Рнк-биомаркеры для наследственного ангионевротического отека
TN2018000358A1 (en) Humanized anti-basigin antibodies and the use thereof.

Legal Events

Date Code Title Description
FD Application lapsed